Published in Clin Immunol on August 01, 2006
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest (2010) 2.00
Homeostasis and effector function of lymphopenia-induced "memory-like" T cells in constitutively T cell-depleted mice. J Immunol (2008) 1.91
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med (2010) 1.86
Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity (2013) 1.75
Neonatal tolerance revisited: a perinatal window for Aire control of autoimmunity. J Exp Med (2009) 1.71
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol (2012) 1.58
CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A (2008) 1.48
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol (2012) 1.45
IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS One (2008) 1.28
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood (2009) 1.15
Regulatory T cells overturned: the effectors fight back. Immunology (2009) 1.13
Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood (2010) 1.13
IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol Rev (2010) 1.12
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler (2014) 1.12
IL-7 in human health and disease. Semin Immunol (2012) 1.08
Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia (2009) 1.06
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.06
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J Clin Cell Immunol (2013) 1.04
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods (2008) 1.03
Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7Rα blockade. PLoS One (2011) 1.01
Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00
Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells. Arthritis Res Ther (2012) 1.00
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci (2015) 0.98
Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol (2011) 0.93
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest (2010) 0.93
T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression. Crit Rev Immunol (2013) 0.91
Loss of immunological tolerance in Gimap5-deficient mice is associated with loss of Foxo in CD4+ T cells. J Immunol (2011) 0.90
Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency--lessons learned from monogenic disorders in mice and men. Curr Opin Immunol (2008) 0.89
Lymphopenia-induced proliferation is a potent activator for CD4+ T cell-mediated autoimmune disease in the retina. J Immunol (2009) 0.89
Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J Clin Invest (2015) 0.88
Both exogenous commensal and endogenous self antigens stimulate T cell proliferation under lymphopenic conditions. Cell Immunol (2011) 0.87
Novel targeted therapies for autoimmunity. Curr Opin Immunol (2009) 0.87
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurol (2016) 0.86
Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody production. Blood (2009) 0.85
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother (2011) 0.85
The role of disease stage, plasma viral load and regulatory T cells (Tregs) on autoantibody production in SIV-infected non-human primates. J Autoimmun (2007) 0.85
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Immunosuppression in islet transplantation. J Clin Invest (2008) 0.83
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS One (2016) 0.82
Immune dysregulation in myelodysplastic syndrome. Hematol Rep (2010) 0.82
Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol (2017) 0.81
Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Autoimmunity (2010) 0.81
IL-7 promotes CD95-induced apoptosis in B cells via the IFN-γ/STAT1 pathway. PLoS One (2011) 0.81
Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. MBio (2016) 0.81
Memory CD4 T cells induce selective expression of IL-27 in CD8+ dendritic cells and regulate homeostatic naive T cell proliferation. J Immunol (2011) 0.80
Ageing combines CD4 T cell lymphopenia in secondary lymphoid organs and T cell accumulation in gut associated lymphoid tissue. Immun Ageing (2014) 0.80
Homeostasis of lymphocytes and monocytes in frequent blood donors. Front Immunol (2012) 0.80
Murine models of Omenn syndrome. J Clin Invest (2007) 0.79
A RAG1 mutation found in Omenn syndrome causes coding flank hypersensitivity: a novel mechanism for antigen receptor repertoire restriction. J Immunol (2008) 0.79
Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis. Curr Infect Dis Rep (2015) 0.79
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol (2016) 0.78
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. Clin Exp Immunol (2011) 0.77
Late onset CNS immune reconstitution inflammatory syndrome in an immunocompetent patient. Front Neurol (2013) 0.77
The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol (2012) 0.76
A two-hit model of autoimmunity: lymphopenia and unresponsiveness to TGF-β signaling. Cell Mol Immunol (2012) 0.76
Modulation of gut microbiota and delayed immunosenescence as a result of syringaresinol consumption in middle-aged mice. Sci Rep (2016) 0.75
Idiopathic CD4 lymphocytopenia with sensorimotor polyneuropathy. Ann Indian Acad Neurol (2016) 0.75
Inaugural description of Cogan syndrome in an HIV-infected person. J Neurol (2008) 0.75
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol (2005) 3.51
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Interleukin-7: from bench to clinic. Blood (2002) 3.01
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84
A role for thymic stromal lymphopoietin in CD4(+) T cell development. J Exp Med (2004) 2.81
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest (2005) 2.48
IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2002) 2.31
Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol (2011) 2.25
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst (2002) 2.24
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98
Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology (2009) 1.95
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood (2013) 1.85
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol (2007) 1.57
Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther (2003) 1.53
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr Blood Cancer (2011) 1.53
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity (2002) 1.44
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer (2005) 1.42
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol (2002) 1.24
A dose effect of IL-7 on thymocyte development. Blood (2004) 1.22
Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice. Blood (2006) 1.19
Interleukin 7 worsens graft-versus-host disease. Blood (2002) 1.16
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood (2009) 1.15
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst (2004) 1.10
In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. J Immunol (2010) 1.09
Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother (2004) 1.08
IL-7 in human health and disease. Semin Immunol (2012) 1.08
Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A (2013) 1.07
Cytokine signals in T-cell homeostasis. J Immunother (2005) 1.07
Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection. J Immunol (2007) 1.07
Current concepts of thymic aging. Springer Semin Immunopathol (2002) 1.04
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J (2010) 1.03
Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res (2004) 1.02
Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood (2004) 1.01
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol (2012) 0.99
Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother (2009) 0.99
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother (2011) 0.98
Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol (2007) 0.96
Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer (2008) 0.96
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res (2006) 0.95
Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol (2008) 0.94
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol (2002) 0.94
Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biol Blood Marrow Transplant (2011) 0.92
Persistent psychological distress in long-term survivors of pediatric sarcoma: the experience at a single institution. Psychooncology (2006) 0.92
GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant (2009) 0.91
Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood (2009) 0.91
Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother (2006) 0.90
Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol (2007) 0.90
Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. Transfusion (2004) 0.90
Ewing sarcoma family of tumors in unusual sites: confirmation by rt-PCR. Pediatr Dev Pathol (2006) 0.88
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol (2012) 0.86
IL-7 in allogeneic transplant: clinical promise and potential pitfalls. Leuk Lymphoma (2006) 0.86
Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. Biomark Med (2014) 0.86
Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis. J Immunol (2012) 0.86
T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2013) 0.86
Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors. PLoS One (2013) 0.84
Immunotherapy of childhood cancer: from biologic understanding to clinical application. Curr Opin Pediatr (2010) 0.84
Perspective on potential clinical applications of recombinant human interleukin-7. Ann N Y Acad Sci (2009) 0.83
Interleukin-7 and immunorestoration in HIV: beyond the thymus. J Hematother Stem Cell Res (2002) 0.83
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol (2012) 0.83
Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol (2009) 0.83
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol (2011) 0.82
Therapy for metastatic ESFT: is it time to ask new questions? Pediatr Blood Cancer (2007) 0.82
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant (2011) 0.82
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am J Immunol (2009) 0.81
T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am (2010) 0.80
Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2014) 0.80
Thymic stromal lymphopoietin is not necessary or sufficient to mediate the thymopoietic effects of keratinocyte growth factor. Blood (2008) 0.78
Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther (2010) 0.78
Current approach to pediatric soft tissue sarcomas. Oncologist (2009) 0.78
Clinical implications of immune reconstitution following hematopoietic stem cell transplantation. Cancer Treat Res (2009) 0.77
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting. J Pediatr Hematol Oncol (2009) 0.77
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. J Immunother (2013) 0.77
Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen. Viral Immunol (2007) 0.76
A robust in vivo model for B cell precursor acute lymphoblastic leukemia. J Clin Invest (2015) 0.75
Cancer therapy-induced immune modulation. Cancer Chemother Biol Response Modif (2005) 0.75
Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfus Med Rev (2010) 0.75
Highlights of the third International Conference on Immunotherapy in Pediatric Oncology. Pediatr Hematol Oncol (2013) 0.75
Adolescents and young adults successfully restore lymphocyte homeostasis after intensive T-cell depleting therapy for cancer. Br J Haematol (2006) 0.75
Analysis of pediatric autologous PBSC apheresis and transplant: age is a major factor affecting post-transplant toxicity. Pediatr Blood Cancer (2011) 0.75